Androgen receptor targeting drugs in castration‐resistant prostate cancer and mechanisms of resistance
- 1 September 2015
- journal article
- research article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 98 (6), 582-589
- https://doi.org/10.1002/cpt.256
Abstract
Reactivated androgen receptor (AR) signaling drives castration‐resistant prostate cancer (CRPC). The novel AR targeting drugs abiraterone and enzalutamide have improved survival of CRPC patients. However, resistance to these agents develops and patients ultimately succumb to CRPC. Potential mechanisms of resistance include the following: 1) Expression of AR splice variants, such as the AR‐V7 isoform, which lacks the ligand‐binding domain; 2) AR missense mutations in the ligand‐binding domain, such as F876L and T877A; and 3) Mutation or overexpression of androgen biosynthetic enzymes or glucocorticoid receptor. Several novel agents may overcome resistance mechanisms. Galeterone acts through multiple mechanisms that include degradation of AR protein and is being evaluated in CRPC patients positive for AR‐V7. EPI‐001 and related compounds inhibit AR splice variants by targeting the N‐terminal transactivation domain of AR. Promising therapies and novel biomarkers, such as AR‐V7, may lead to improved outcomes for CRPC patients.Keywords
Funding Information
- National Institute of General Medicine Sciences (NIGMS) (T32GM086330)
This publication has 72 references indexed in Scilit:
- Overcoming mutation-based resistance to antiandrogens with rational drug designeLife, 2013
- Increased Survival with Enzalutamide in Prostate Cancer after ChemotherapyNew England Journal of Medicine, 2012
- Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trialThe Lancet, 2011
- Abiraterone and Increased Survival in Metastatic Prostate CancerNew England Journal of Medicine, 2011
- Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind studyThe Lancet, 2011
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate CancerNew England Journal of Medicine, 2010
- Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancerTrends in Endocrinology & Metabolism, 2010
- Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 studyThe Lancet, 2010
- Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established targetThe Lancet Oncology, 2009
- Molecular determinants of resistance to antiandrogen therapyNature Medicine, 2003